BTG strengthens biotech venture arm

Michael Garrett joins the technology developer to head up its biotech and healthcare unit.

BTG, the technology commercialisation company listed on the London Stock Exchange, has appointed Michael Garret Global Vice President of New Ventures and Business Development for the group’s health, medical and biotech unit.

Garrett, a chartered European and UK patent attorney, joins from Aventis, where he worked as a fund manager running Genavent, a life science venture fund jointly owned by Aventis and Société Générale.

“Within the medical and life sciences business, there is significant scope for venture activity. BTG has a lot of expertise in spotting opportunity and helping technologies come to market”, Garret commented on his appointment.

BTG has been in the business of commercialising new technologies since 1949. The group helps develop new technology and aims to make money by licensing the rights to new technologies or setting up new ventures.

Last year, the company completed a rights issue raising £120m for new investments.